1062-42 Adverse events in patients with normal renal function are increased with modest increases in creatinine clearance after percutaneous coronary intervention  by Bartholomew, Beth A et al.
JACC March 3, 2004 ABSTRACTS - Angiography & Interventional Cardiology  47A
Angiography &
 Interventional Cardiology
in 27 patients (111 lesions). The mean stent length per patient was 87.4±45.2mm. At 30
days the cumulative MACE rates were 10.3%: 7.1% patients developed a non–Q, 1.9% a
Q-wave MI, 0.6% died for non-cardiac reasons and 0.6% had a repeat revascularization.
Clinical follow-up was obtained in all eligible 112 patients treated on 359 lesions at a
mean time of 6.5±2.2 months. The cumulative MACE rate was: 3 deaths (2.7%, 1 for car-
diac reasons) and 4 (3.6%) MI. Target lesion revascularization (TLR) was performed in
24 (6.7%) lesions in 16 patients (14.3%). Target vessel revascularization was required in
18 (16.1%) patients due to TLR of lesions treated with SES or to disease progression
(1.8% of patients). Cumulative total MACE rate was 22.3%. Cox regression analysis
revealed total stent length per patient as the most powerful independent predictor of
MACE. Overall stent thrombosis occurred in 3 (1.9%) patients.
CONCLUSION
Multivessel SES implantation can be safely performed on patients with complex coronary
artery disease. The need for revascularization increases due to cumulative effect of TLR
on patients with multiple lesions.
1044-61 Creatine Kinase-MB Enzyme Elevation After 
Percutaneous Coronary Interventions Using Sirolimus-
Eluting Stents
Goran Stankovic, Dejan Orlic, Ioannis Iakovou, Nicola Corvaja, Giuseppe Sangiorgi, 
Alaide Chieffo, Flavio Airoldi, Matteo Montorfano, Mauro Carlino, Giancarlo Vitrella, 
Iassen Michev, Antonio Colombo, Emo, Centro Cuore Columbus, Milano, Italy, San 
Raffaele Hospital, Milano, Italy
Objective: To evaluate predictors of periprocedural creatine kinase MB isoenzyme (CK-
MB) elevation following implantation of sirolimus-eluting stents (SES).
Methods: We studied 320 consecutive patients who underwent SES implantation in 722
coronary lesions between April 2002 and January 2003. Univariate and multivariate
logistic regression analyses were used to determine independent predictors of CK-MB
elevation from clinical, angiographic and procedural covariates.
Results: CK-MB elevation > 3 times upper limit of normal occurred in 42 patients
(13.1%). Those patients less frequently received elective glycoprotein IIb/IIIa agents (GP
IIb/IIIa) (19% vs. 43%, P=0.001) and had longer SES implanted (total stent length per
patient 86 vs. 59mm, P=0.001). Univariate predictors of CK-MB elevation were: multives-
sel disease, OR 2.05 (95%CI 1.05-3.99, P=0.032); number of treated lesions, OR 1.43
(95%CI 1.17-1.76, P=0.001); de-novo lesion, OR 1.80 (95%CI 1.02-3.18, P=0.034); total
stent length per patient, OR 1.13 (95%CI 1.01-1.20, P=0.001) and elective use of GP IIb/
IIIa, OR 0.31 (95%CI 0.14-0.70, P=0.003). Multivariate analysis indicated that total stent
length per patient (OR 1.02 (95%CI 1.01-1.03, P=0.001, predisposing factor) and elective
use of GP IIb/IIIa (OR 0.21 (95%CI 0.08-0.50, P=0.001, protective factor) were indepen-
dent predictors of CK-MB elevation. At 30 days and 9.5 months follow-up patients with
and without periprocedural myonecrosis had similar composite MACE (death/myocardial
infarction/repeat revascularization, 2.4% vs. 1.4%, P=0.65 and 21.4% vs. 16.9%, P=0.47,
respectively).
Conclusion: In patients treated with SES, CK-MB elevation correlates with implantation
of longer stents, while elective use of GP IIb/IIIa lowers that risk.
1044-62 Post-Market Surveillance of the CYPHER Sirolimus-
Eluting Stent: One-Month Clinical Results From the 
United States
Stanley Katz, Marco A. Costa, Emerson C. Perin, Stephen R. Ramee, Peter B. Berger, 
Peter Block, Northshore Hospital, Manhasset, NY
Background: e-CYPHER is a global, internet-based registry collecting data on the use
of the CYPHER™ Sirolimus-eluting Stent (CYPHER) in routine clinical practice. In the
US, e-CYPHER is the database tool for the FDA-mandated post market surveillance
requirement.
Methods: The US post market surveillance includes 2000 patients at up to 75 centers.
Data are recorded in the e-CYPHER registry from consecutive patients treated with at
least one CYPHER stent, with clinical follow-up at 1, 6 and 12 months. Demographic,
treatment, and adverse event information are collected. Events reported from US
patients are adjudicated by an independent clinical events committee.
Results: Enrollment into the US registry began on August 6, 2003. Currently, 110
patients have been enrolled at 6 sites. One month data from the US will be available at
the time of presentation. Site reported one month event rates from 3330 patients treated
at sites throughout Europe, Latin America, Asia Pacific and Middle East are presented
below. 
Conclusions: The e-CYPHER registry is the largest ongoing registry of drug-eluting 
stent usage, and will provide ongoing safety information for the CYPHER stent.
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1062-41 The Impact of Renal Insufficiency on Long-Term 
Survival of Patients With Diabetes Undergoing 
Percutaneous Coronary Intervention
Jeffrey S. Berger, Timothy A. Sanborn, Warren Sherman, David L. Brown, Beth Israel 
Medical Center, New York, NY
Introduction: Diabetes and renal insufficiency are each associated with an increased
risk of mortality among patients with coronary artery disease (CAD). However, the impact
of coexistent renal disease and diabetes in patients with established CAD is not well
understood. We sought to evaluate the impact of renal insufficiency on survival of
patients with diabetes and CAD. Methods: Three hospitals in New York City contributed
data on 1142 consecutive diabetic patients undergoing percutaneous coronary interven-
tion (PCI) in 1998-9. Renal disease was defined by a creatinine > 2.5mg/dl and included
patients on chronic dialysis. The primary end-point was all-cause mortality at 3-year fol-
low-up. Results: Among diabetics, renal disease was present in 75 patients (6.6%).
There was no difference in age, race, or gender between groups. Diabetics with renal dis-
ease were more commonly obese (41.3% vs. 30.7%, P=0.079) and less likely to be
smokers (1.3% vs. 9.4%, P=0.018). Hypertension and stroke were not different between
groups. Patients with renal disease had a greater prevalence of vascular disease (25.3%
vs. 9.7%, P<0.001), prior heart failure (22.7% vs. 7.7%, P<0.001) and previous cardiac
surgery (33.3% vs. 21.6%, P=0.019). Diabetics with renal disease presented more often
with 3-vessel CAD (36% vs. 23%, P=0.009). Mean ejection fraction was lower in diabet-
ics with renal disease (46% vs. 50%, P<0.001). Angiographic success was 97% in both
groups. In-hospital mortality was significantly greater among diabetics with renal disease
than diabetics without renal impairment (6.7% vs. 0.6%, P<0.001). At 3-year follow-up,
mortality for diabetics with renal disease was 44% vs. 11% in diabetics without renal
impairment (log-rank P<0.0001). On Cox proportional hazards analysis, renal disease
among diabetics was an independent predictor of mortality (Hazard Ratio, 3.067, 95%
Confidence Interval, 1.987-4.733, P<0.001). Conclusion: Renal disease in diabetics
with CAD is independently associated with a 3-fold increase in the hazard of death. The
increased mortality of CAD diabetics with renal impairment should stimulate further
research concerning appropriate treatment and surveillance regimens.
1062-42 Adverse Events in Patients With Normal Renal Function 
Are Increased With Modest Increases in Creatinine 
Clearance After Percutaneous Coronary Intervention
Beth A. Bartholomew, Cindy L. Grines, Judith A. Boura, William W. O'Neill, William 
Beaumont Hospital, Royal Oak, MI
Background: Creatinine clearance (CrCl) reduction after percutaneous coronary inter-
vention (PCI) is associated with increases in adverse events in patients with chronic kid-
ney disease. However, the impact of CrCl changes after PCI in patients with normal
baseline renal function is not well defined.
Methods: Data was prospectively collected from 1993 to 2003 on 20,479 patients under
going PCI. Patients were excluded for an estimated baseline CrCl <90 ml/min, prior his-
tory of renal failure or dialysis, coronary artery bypass surgery, ejection fraction <30%,
shock, no reflow, and residual stenosis >50%. Patients were grouped by CrCl reduction
for comparison. Multivariate analysis was used to determine the impact on in-hospital
adverse events.
Results: The incidence of a > 25% CrCl reduction after PCI in patients with previously
normal renal function was 0.08% (262/3658). Independent predictors with an odds ratio
>2 were: male gender (P value<0.001), intra-aortic balloon pump use (P value=0.01),
and age over 70 (P value=0.0004). Patients with a decrease in CrCl had increased
events as shown below. 
One Month Event Rates
(3330 patients)
MACE (%) 1.80
Death (%) 0.66
MI (%) 0.69
TLR (%) 0.24
CABG (%) 0.21
SAT (%) 0.87
Adverse Events with Decreasing Creatinine Clearance 
Creatinine Clearance Decrease
Adverse Events 0-25% > 25-<50% >50% P value
N=3396 N=231 N=31
Death 0.3% 0.9% 13.0% <0.0001
Bleeding 0.7% 1.3% 16.0% <0.0001
Hospitalization >4days 12% 30% 56% <0.0001
Myocardial Infarction 0.5% 0.4% 3.2% 0.16
Reoccclusion 0.4% 0.4% 0.0% 0.62
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Conclusions: CrCl reduction after PCI is infrequent in patients with normal baseline
renal function. A modest decrease in CrCl, even after adjusting for other variables, is
associated with significant increases in mortality, bleeding complications and a longer
length of hospitalization. The association with intra-aortic balloon pump use suggests an
embolic mechanism which warrants further investigation.
1062-43 Preprocedure Hyperglycemia Is Stongly Assoicated 
With Restenosis After Coronary Intervention in 
Diabetics
Arvind K. Sharma, Joseph Lindsay, Daniel A. Canos, Ellen Pinnow, Sue Apple, Giacomo 
Ruotolo, Mohan Nandalur, Mevan Wijetunga, Howard Cooper, Ron Waksman, 
Washington Hospital Center, Washington, DC
Background:Restenosis rate after percutaneous coronary intervention (PCI) in diabetic
pts is at least twice that of nondiabetics. We explored potential relationships between res-
tenosis and metabolic factors in diabetics. Methods:Fasting blood samples were
obtained from 162 diabetics (98 men, mean age 62.8±10.7) immediately prior to PCI and
analyzed for insulin, glucose, and hemoglobin A1c (A1c). Insulin resistance (IR) was cal-
culated from the HOMA formula. All pts had successful PCI. Baseline clinical, procedural
and follow-up information was recorded. The primary end point was target vessel revas-
cularization (TVR) rate by 9 months. Results:The insulin level was increased in virtually
all pts(mean 21.0±15.2 µU/ml). No association between TVR and insulin levels or calcu-
lated IR was identified. Only blood glucose level was significantly associated with TVR
(p<0.035).This effect was independent of A1c levels (Figure).The 9-month death plus
nonfatal infarction rate was low (4.2%). No association with the independent variables
could be shown. Conclusion:These data do not support a role for either fasting insulin
level or calculated IR in restenosis. Glucose levels >135 mg/dl were associated with high
TVR rates regardless of A1c levels. The metabolic milieu at the time of the PCI may influ-
ence restenosis.
1062-44 Hypothermia, but Not N-Acetylcysteine or Fenoldopam, 
Prevents Experimental Contrast-Induced Nephropathy
Michael W. Dae, Dong W. Gao, Carol A. Stillson, Gregg W. Stone, Philip C. Ursell, 
University of California at San Francisco, San Francisco, CA, Cardiovascular Research 
Foundation, New York, NY
Background: Contrast-induced nephropathy (CIN) is common after angiographic proce-
dures in high-risk patients. Other than hydration, there is no effective treatment to prevent
CIN. We tested the hypothesis that hypothermia would protect the kidneys from CIN.
Methods: We studied a total of 29 rabbits: controls 39°C, pretreatment with N-Acetylcys-
teine 39°C (NAC, 120 mg/kg over 1 hour, then 11 mg/kg/hr x 4 hours), Fenoldopam 39°C
(0.05 µg/kg/hr x 4 hours), and hypothermia (32°C; 35°C). Hypothermia was induced
using an esophageal heat exchange catheter (Radiant Medical, Inc). Core temperature
was measured in the descending aorta. Rabbits were cooled to target temperature prior
to contrast injection, maintained for 3 hours, then rewarmed. NAC was infused starting 2
hours before contrast injection (Fenoldopam 1 hr before). Iopromide (Ultravist,10.0 g I/kg)
was injected via femoral vein. Serum creatinine (Cr, mg/dl) was measured at baseline,
24, and 48 hours post injection. Kidneys were removed at 48 hours for histology.
Results: Cr results are shown in the table. Significant increases in Cr and extensive
tubular necrosis occurred in controls, NAC, and Fenoldopam, but not in the hypothermic
animals.
Conclusions: Hypothermia started prior to contrast injection provided complete protec-
tion of the kidneys in this experimental model of CIN, and proved superior to NAC and
Fenoldopam. These results suggest that hypothermia may provide a new and effective
strategy for prevention of CIN in high-risk patients. 
1062-45 Prevention of Contrast-Agent-Induced Nephropathy in 
Patients Undergoing a Coronary Procedure by Ascorbic 
Acid
Konstantinos S. Spargias, Elias Alexopoulos, Stamatis Kyrzopoulos, Panagiotis Iakovis, 
Athanassios Manginas, Vassilios Voudris, Gregory Pavlides, Demetrios Kremastinos, 
Dennis V. Cokkinos, Onassis Heart Centre, Athens, Greece
Background: Contrast agents can cause a reduction in renal function that may be due to
generation of reactive oxygen species. There is some evidence suggesting that the
administration of the antioxidant acetylcysteine prevents this renal impairment. The
action of other antioxidant agents, such as ascorbic acid, has not been investigated.
Methods: We conducted a randomized, double-blind, placebo-controlled, prospective
study of ascorbic acid in 231 patients who underwent coronary angiography or interven-
tion and had a serum creatinine concentration > 1.2 mg/dl. Ascorbic acid (3gr at least 2
hours before the procedure, and 2 gr in the night and the morning after the procedure) or
placebo was administered orally. An acute contrast-agent-induced reduction in renal
function was defined as an at least 0.5 mg/dl or a 25% increase in the baseline serum
creatinine concentration measured 2-5 days after the procedure.
Results: Eleven of the 118 patients (9.3%) in the ascorbic acid group, and 23 of the 113
patients (20.4%) in the placebo group achieved the study end-point (p=0.02, relative risk
0.38, 95% confidence interval 0.17 to 0.85). The mean serum creatinine concentration
increased significantly in the placebo group [1.36 (SD:0.50) to 1.50 (0.54) mg/dl,
p<0.001], but not in the ascorbic acid group [1.46 (0.52) to 1.52 (0.64) mg/dl, p=0.20].
The mean increase in the serum creatinine concentration in the placebo group was
greater than that in the ascorbic acid group [0.14 (0.30) vs. 0.06 (0.35) mg/dl, p=0.001].
Conclusion: Prophylactic oral administration of ascorbic acid may protect against con-
trast-agent-induced nephropathy in high-risk patients undergoing a coronary procedure.
1062-46 Preventive Effects of Rosiglitazone on Restenosis After 
Coronary Stent Implantation in Patients With Type 2 
Diabetes Mellitus
Young-Guk Ko, Donghoon Choi, Yangsoo Jang, Sung-Hee Choi, Soo-Kyung Kim, Bong-
Soo Cha, Yonsei University College of Medicine, Seoul, South Korea
Background: After coronary stenting, the restenosis rate is known to be higher in DM
than non-DM patients due to excessive intimal hyperplasia. We investigated the efficacy
of rosiglitazone for preventing restenosis after coronary stenting in diabetic patients.
Methods : We conducted a prospective case-controlled trial involving 95 diabetic
patients (control n=48, rosiglitazone (4 mg per day) group n=47) undergoing coronary
stenting. Serum glucose level and cholesterol were tried to be optimized using additional
hypoglycemic agents and statins. An angiographic follow-up was performed at six
months. Results: A follow-up angiography was performed in 83 patients including 45
patients with 55 lesions in control group (m:f = 31:11, age 59.9±9.3 years), and 38
patients with 51 lesions in the rosiglitazone group (m:f=24:18, age 60.9±9.3 years). The
baseline clinical profile and blood chemistry between two groups were not different.
Baseline angiographic data of control and rosiglitazone group were as following : refer-
ence diameter 3.15±0.49 vs. 3.16±0.49 mm (p=NS), minimal lumen diameter (MLD)
0.65±0.41 vs. 0.83±0.57 mm (p=NS), diameter stenosis (DS) 79.4±12.8 % vs. 74.4±15.8
%, lesion length 16.48±5.16 vs. 19.02±6.09 mm (p<0.05). There was no difference in
MLD or acute gain after coronary stenting between the two groups. The follow-up angiog-
raphy showed a significantly lower binary restenosis rate in the rosiglitazone group than
the control group (17.6% vs. 38.2%, P = 0.03). The follow-up DS (24.2 ± 23.2% vs. 42.9
± 32.2%, P = 0.001) and loss index (0.49±0.41 vs. 0.27±0.30, p=0.008) were also lower
in the rosiglitazone group. Major adverse cardiac events occurred less frequently in the
rosiglitazone group (10.5% vs 20%, p=0.244) at 6 months, although it was not statistically
significant. The serum glucose, insulin, lipid concentrations were similar at 6- month fol-
low-up in the both groups. Conclusions: Rosiglitazone effectively reduced restenosis in
diabetic patients after coronary stenting. This effect is probably related to pleotrophic
property of rosiglitazone rather than its hypoglycemic effect.
1062-47 Marked Improvements in In-Hospital Outcomes 
Following Contemporary Percutaneous Coronary 
Intervention in Patients With Diabetes
David O. Williams, Alice K. Jacobs, Helen A. Vlachos, Katherine M. Detre, Rhode Island 
Hospital, Providence, RI
Background: Presence of diabetes mellitus (DM) has been associated with adverse
results among patients (pts) treated by percutaneous coronary intervention (PCI).
Methods: We sought to determine whether advances in PCI over time have impacted in-
hospital clinical outcomes of pts with DM. Pts with DM were identified and analyzed in the
1985-86 PTCA Registry (n=325) and in the 1997-2001 enrollment waves of the NHLBI
Dynamic Registry (n=622).
Results: Pts in the Dynamic Registry were older (64.1 vs. 60.7 years, p<0.001), more
often had history of hypertension (80.0% vs. 61.8%, p<0.001), severe concomitant non-
cardiac disease (45.5% vs. 9.5%, p<0.001), and lower LV ejection fractions (50.4% vs.
57.8%, p<0.001). No differences were observed in gender, prior CABG, history of CHF,
number of vessels diseased or mean number of lesions. AMI was more often an indica-
tion for PCI in the Dynamic Registry (27.7% vs. 7.4%, p<0.001) and procedures were
more often emergent or urgent. In the Dynamic Registry, fewer lesions were attempted
per pt (1.4 vs. 1.7, p<0.001) and lesion location was less often the LAD (36.8% vs.
45.3%, p<0.05). Stents were used in 87.5% of Dynamic Registry pts and in no 1985-86
pts. Angiographic success was higher in the Dynamic Registry (94.8% vs. 78.1%,
p<0.001) and abrupt closure (0.9% vs. 2.2%, p<0.05), death (1.9% vs. 4.3%, p<0.05), MI
(1.0% vs. 7.4%, P<0.001) and in-hospital CABG (0.8% vs. 6.2%, p<0.001) were less
common.
Conclusions: Although pts with DM having contemporary PCI were older and had more
Cr Baseline Cr 24 hrs Cr 48 hrs
Control, 39°C (n=6) 1.1±0.2 3.9±1.8* 5.8±3.3*
NAC (n=6) 0.8±0.1 2.3±0.9* 4.3±1.6*
Fenoldopam (n=6) 1.0±0.2 2.8±1.0* 5.3±1.3*
Hypo-35°C (n=5) 0.8±0.1 1.1±0.2**# 0.9±0.2#
Hypo-32°C (n=6) 1.2±0.2 1.1±0.3# 1.0±0.3#
*P<0.01 vs baseline
**P=0.05 vs baseline
#P<0.01 vs
Control,NAC,
Fenoldopam
